Microgel Encapsulation via Flow Focusing Nozzle Shielding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for encapsulating cells and bioactive agents in microgels face challenges such as limited control over the local cellular environment, cytotoxic effects from UV-based crosslinking, and difficulty in encapsulating large cell clusters like islets due to clogging in microfluidic channels, while also struggling with immunoisolation and controlled release of bioactive molecules.
Innovation Solution
A microfluidic platform that uses a flow focusing nozzle to create monodisperse microgel droplets by shielding the macromer phase from the crosslinker phase until flow instability occurs, allowing for covalent crosslinking and encapsulation of cells and bioactive agents, with tunable size and permeability, and the use of biodegradable peptide crosslinkers for controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If UV-based free radical polymerization is used for crosslinking, then crosslinking efficiency is improved, but cytotoxic effects on encapsulated cells occur
Solution Approach 1:
The patent replaces UV-based free radical polymerization with a chemical crosslinking system using cysteine-containing peptides and transglutaminase enzyme. This substitution eliminates the need for UV irradiation and free radicals, thereby removing the cytotoxic effects while achieving effective crosslinking through enzymatic catalysis and chemical bonding between glutamine and lysine residues.
Solution Approach 2:
The patent changes the crosslinking mechanism from physical/chemical (UV-induced free radicals) to biochemical (enzyme-catalyzed crosslinking). By using transglutaminase to catalyze the formation of isopeptide bonds between specific amino acid residues, the system achieves crosslinking under physiological conditions that are non-toxic to encapsulated cells.
2Volume of moving object
If microfluidic devices are used to generate small microgel droplets, then encapsulation volume is minimized, but large cell clusters like islets cannot be encapsulated due to channel clogging
Solution Approach 1:
The patent segments the crosslinking process from the droplet generation process. Droplets are first formed in a microfluidic device with controlled size and monodispersity, then the crosslinking occurs after droplet formation. This segmentation allows the use of small microfluidic channels for droplet generation while accommodating large cell clusters, as the crosslinking step does not require passage through narrow channels.
Solution Approach 2:
The patent performs droplet generation and formation as a preliminary action before crosslinking. By first creating monodisperse droplets containing cells and bioactive agents, then subsequently crosslinking them, the system minimizes encapsulation volume while avoiding channel clogging issues that would occur if crosslinking happened before or during droplet formation with large cell clusters.
3Ease of manufacture
If alginate microencapsulation is used, then ease of manufacture and biotolerance are improved, but control over local cellular environment via bioactive molecules is limited
Solution Approach 1:
The patent uses a composite hydrogel system combining PEG-based polymers with cysteine-containing peptides and transglutaminase enzyme. This composite material system provides both the ease of manufacture characteristic of alginate systems and the adaptability to control cellular microenvironment through bioactive molecule incorporation, as the PEG backbone can be functionalized with various bioactive peptides and growth factors.
Solution Approach 2:
The patent incorporates bioactive molecules such as RGD peptides, IKVAV peptides, and other cell-adhesive ligands at specific locations within the hydrogel matrix. This local functionalization allows control over cellular behavior, adhesion, and differentiation at specific sites within the encapsulation structure, enabling precise control over the local cellular environment while maintaining ease of manufacture.
4Adaptability or versatility
If synthetic hydrogel encapsulation is used, then tunability and immunoisolation are improved, but cytotoxic crosslinking methods are required
Solution Approach 1:
The patent replaces toxic chemical crosslinking methods with enzymatic crosslinking using transglutaminase. This substitution maintains the tunability and immunoisolation benefits of synthetic hydrogels while eliminating cytotoxic effects, as the enzyme-catalyzed crosslinking occurs under physiological conditions without generating harmful byproducts or requiring harsh chemicals.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the creation of biocompatible, monodisperse microgel droplets that maintain cell viability and function, allow for selective permeability, and facilitate controlled release of bioactive agents, suitable for regenerative medicine and drug delivery applications.
Implementation Method 1
flow instability occurs and macromer phase droplets form
Implementation Method 2
the crosslinker diffuses from the crosslinker phase into the droplets in an effective amount to covalently crosslink the macromer into a microgel network
Implementation Method 3
form microgel droplets by oil-water emulsion
Data Source
AI summary
Methods of encapsulating cargo in a microgel droplet, microgel droplets prepared according the provided methods, and methods of use thereof are disclosed. The methods of preparing cargo-encapsulated microgels generally include flowing through a flow-focusing nozzle of a microfluidic device a macromer phase, an oil phase, and a crosslinker phase to form microgel droplets by oil-water emulsion. The phases are pumped, injected, or flowed through the microfluidic device such that as the macromer phase approaches the flow focusing nozzle, the co-flowing oil phase shields the macromer from contact with the crosslinker phase until flow instability occurs and macromer phase droplets form. After flow instability occurs, the crosslinker diffuses from the crosslinker phase into the droplets in an effective amount to covalently crosslink the macromer into a microgel network encapsulating the cargo in the crosslinked macromer. Microgels prepared according to the disclosed methods and methods of use thereof are also provided.